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  ABSTRACT 
  Background      The P140 phosphopeptide issued from 
the spliceosomal U1-70K small nuclear ribonucleoprotein 
protein displays protective properties in MRL/lpr lupus-
prone mice. It binds both major histocompatibility class 
II (MHCII) and HSC70/Hsp73 molecules. P140 peptide 
increases MRL/lpr peripheral blood lymphocyte apoptosis 
and decreases autoepitope recognition by T cells.   
  Objective      To explore further the mode of action of P140 
peptide on HSC70+ antigen-presenting cells.   
  Methods      P140 biodistribution was monitored in real 
time using an imaging system and by ﬂ  uorescence and 
electron microscopy. Fluorescence activated cell sorting 
and Western blotting experiments were used to evaluate 
the P140 effects on autophagic ﬂ  ux markers.   
  Results      P140 ﬂ  uorescence accumulated especially in 
the lungs and spleen. P140 peptide reduced the number 
of peripheral and splenic T and B cells without affecting 
these cells in normal mice. Remaining MRL/lpr B cells 
responded normally to mitogens. P140 peptide decreased 
the expression levels of HSC70/Hsp73 chaperone and 
stable MHCII dimers, which are both increased in MRL/
lpr splenic B cells. It impaired refolding properties of 
chaperone HSC70. In MRL/lpr B cells, it increased the 
accumulation of the autophagy markers p62/SQSTM1 
and LC3-II, consistent with a downregulated lysosomal 
degradation during autophagic ﬂ  ux.   
  Conclusion      The study results suggest that after P140 
peptide binding to HSC70, the endogenous (auto)
antigen processing might be greatly affected in MRL/
lpr antigen-presenting B cells, leading to the observed 
decrease of autoreactive T-cell priming and signalling via 
a mechanism involving a lysosomal degradation pathway. 
This unexpected mechanism might explain the beneﬁ  cial 
effect of P140 peptide in treated MRL/lpr mice.           
  INTRODUCTION 
  Systemic lupus erythematosus is a multifacto-
rial (multigenic) and highly polymorphic systemic 
autoimmune disorder. It affects multiple organs, 
including skin, muscle, joints and vital internal 
organs such as kidneys and heart. Current pharma-
cological treatments are largely palliative and result 
in non-speciﬁ  c immunosuppression. The goal today 
is to design more speciﬁ  c and effective treatments. 
  P140 peptide is a 21-mer fragment of the spli-
ceosomal U1-70K small nuclear ribonucleoprotein 
protein that signiﬁ   cantly ameliorates clinical and 
biological manifestations in autoimmune patients 
with systemic lupus erythematosus and enhances 
survival in lupus-prone mice.    1        2    This peptide con-
tains a phosphoserine residue at position 140, a 
modiﬁ  cation  that  speciﬁ   cally occurs at an early 
stage of apoptosis, before the cleavage of the 
C-terminal part of the protein by caspase-3 and the 
dephosphorylation of other serine residues by a 
PP1 phosphatase-mediated mechanism.    3    Originally 
thought to act solely via the modulation of intrac-
ellular signalling induced by αβ autoreactive T-cell 
receptor (TCR) engagement,    2        4    P140 was unexpect-
edly found to interact selectively with the consti-
tutive heat-shock HSC70/Hsp73 protein.    5    By a 
granzyme-B and caspase-dependent mechanism, it 
induces in Fas-deﬁ  cient MRL/lpr lupus mice apopto-
sis of B cells and CD4, CD8 or double negative (DN) 
αβTCR+/CD4/CD8/B220+ T lymphocytes through 
a regulatory circuit involving γδT cells.    5    Intravenous 
P140 peptide administration into young MRL/lpr 
mice thus causes T- and B-cell egress from periph-
eral blood but does not affect T-cell priming, and 
does not interfere with the ability of P140-treated 
mice to resist to an infectious viral challenge.    6    P140 
also downregulates the expression of programmed 
death 1 (PD-1/CD279) receptor, a molecule of the 
CD28 family, which is overexpressed at the sur-
face of MRL/lpr CD4 T cells.    5    P140 peptide thus 
displays various effects on the immune system that 
probably interfere with several, yet unidentiﬁ  ed, 
molecular pathways leading ﬁ  nally to a decreased 
T-cell autoreactivity and to signiﬁ  cantly lower levels 
of autoantibodies to native DNA. 
  In the postulated P140 mode of action, bind-
ing to the chaperone HSC70 protein seems to be 
central. The implication of or any defect of the 
HSC70 pathway in regulating immune functions in 
lupus is not documented. It is not known either if 
HSC70-chaperoned molecules, such as other Hsps 
and major histocompatibility complex (MHC) 
molecules, are affected by P140–HSC70 binding. 
To address these major questions, we evaluated 
the effect of P140 administration on the expres-
sion of HSC70 and MHCII molecules, and studied 
the possible inﬂ  uence of P140 on   autophagosomal 
pathways implicated in the endogenous MHCII 
loading. Since HSC70 is involved in certain phases 
of these pathways, we expected that binding of 
P140 to HSC70 might alter the delivery of intracel-
lular material into the endosomal/lysosomal path-
way and therefore thwart the ﬁ  nal presentation of 
self-antigens to autoreactive T cells.   
  METHODS 
    Synthetic peptides and biochemical assays 
  Peptides were assembled and puriﬁ   ed as des-
cribed.    1        5    The P140 peptide was also synthesised 
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  RESULTS 
    In vivo P140 peptide effects and biodistribution 
  We reported previously that intravenous administration of 
P140 to MRL/lpr mice signiﬁ   cantly improves their clinical 
and biological manifestations and prolongs their survival.    1    
We show here that P140 signiﬁ   cantly decreases vasculitis 
with fewer perivascular inﬂ  ammatory inﬁ  ltrates in kidneys 
(  ﬁ  gure  1A  ; p=0.0079), slows down glomerulonephritis (  ﬁ  g-
ure 1B  ; p<0.0001) and reduces the appearance of dermatitis 
(  ﬁ  gure 1C  ). 
  P140 biodistribution after intravenous administration to 
MRL/lpr mice was monitored in real time by bioimaging in liv-
ing mice. Alexa Fluor  633  -labelled P140 accumulated particularly 
in the lungs and spleen, a distribution that was not observed 
with an unrelated peptide (  ﬁ  gure 1D  ; online supplementary 
ﬁ  gure S1; similar results were obtained in 6- and 12-week-old 
MRL/lpr mice). Fluorescence in the spleen was detectable 10–15 
min after P140 injection and remained for at least 90–120 min. 
Similar results were observed in MRL/lpr mice that received 
rhodamine-labelled P140 intravenously (  supplementary ﬁ  gure 
S2A). In the spleen, ﬂ  uorescence was mainly localised in the 
lymphoid white pulp, mostly in the mantle and marginal zones 
(supplementary ﬁ   gure S2B). It co-localised essentially with 
splenic B cells and resident macrophages (  ﬁ  gure 1E  ) as well as 
with CD11b- and F4/80-positive cells. The macrophage F4/80 
antigen is absent from   macrophages located in T-cell areas of 
the spleen and lymph nodes (LNs). Thus, P140 preferentially 
homes in organs enriched in   activated B cells and, more gener-
ally, in   antigen-presenting cells (APCs). 
  P140 administration signiﬁ   cantly decreased peripheral 
hypercellularity in MRL/lpr mice (supplementary ﬁ  gure S3; no 
effect was seen with the ScP140 scrambled analogue). B cells, 
T cells (including γδT cells and DN T cells) and granulocytes/
monocytes were affected. In CBA/J control mice, however, 
even an overdosage of P140 did not produce any observable 
effect while, in contrast, the glucocorticoid prednisolone, 
which is active in MRL/lpr mice,    9    and immunosuppressant 
ciclosporin A induced a decrease of PBL counts in both CBA/J 
and MRL/lpr mice (  ﬁ  gure 1F  ). Peripheral B and T cells from 
non-treated MRL/lpr mice and remaining peripheral B and T 
cells from P140-treated mice responded equally well ex vivo to 
B-cell mitogen and slightly less well (p=0.024) to T-cell mito-
gen (  ﬁ  gure 1G  ). No effect of P140 was observed in CBA/J mice. 
This was not the case for ciclosporin A, which signiﬁ  cantly 
affected the abilities of peripheral B and T cells from MRL/
lpr and CBA/J mice to respond to mitogens, and prednisolone, 
which affected the abilities of CBA/J B and T cells to respond 
to mitogens. In the spleen, the proportion of T cells (including 
activated T cells) was signiﬁ  cantly decreased after P140 treat-
ment (p=0.0022;   ﬁ  gure 1H  ). The percentage of B cells remained 
unchanged.  
    HSC70 and MHCII overexpression in MRL/lpr mice is reduced 
after P140 treatment 
  P140 binds to HSC70 protein both at 25°C and 4°C (  ﬁ  gure 2A  ), 
suggesting that P140 recognises both intracellular and cell 
surface-expressed HSC70 (result obtained with splenocytes, 
LN cells and PBLs). Fluorescent staining of P140 and HSC70 
  co-localises in the cytoplasm of freshly isolated, permeabi-
lised MRL/lpr PBLs 1 h after intravenous administration of 
Alexa Fluor  488  -labelled P140 (  ﬁ  gure 2B1  ). This co-localisation 
was conﬁ  rmed by immunoﬂ  uorescence and immunoelectron 
microscopy (    ﬁ  gure 2B2, C  ), and was mainly cytoplasmic. 
with a cysteine residue added at its N-terminus. The luciferase 
renaturation assay was as described    7        8    using either intact or 
heat-denatured luciferase and rabbit reticulocyte lysate in 
the presence of increasing concentrations of P140 peptide. 
Luciferase activity was determined using Bright-glo reagent 
(Promega, Charbomières, France   ).  
    In vivo experiments and cell studies 
  Protection experiments and clinical monitoring have been 
described previously.    1    All experimental protocols were carried 
out with the approval of the local Institutional Animal Care and 
Use Committee (CREMEAS). The renal pathology was evaluated 
by measuring proteinuria levels and observing vasculitis corre-
sponding to the area of cell inﬁ  ltrates. For in vivo imaging, Alexa 
Fluor  633  -labelled P140 was injected through the   retro-orbital 
venous sinus of anaesthetised mice. Mice were immediately 
transferred into the cabinet of the NightOwl Bioimager (Berthold 
Technologies, Thoiry, France   ) and images were taken periodi-
cally for 3 h. Mice were then killed to collect organs for ﬁ  nal 
ﬂ  uorescence acquisition and validation of biodistribution. Signal 
intensity was evaluated using the Indigo software. 
  Histology was carried out on frozen section of organs collected 
from MRL/lpr mice that received rhodamine-labelled P140 intra-
venously. For co-localisation experiments, spleen sections were 
permeabilised and incubated with either ﬂ  uorescein isothiocya-
nate (FITC)-labelled anti-B220 antibody or biotin-labelled anti-
CD3e antibodies, followed by Alexa Fluor 647  -labelled streptavidin, 
or biotin-labelled anti-MOMA-1/CD169 antibodies speciﬁ  c for 
metallophilic macrophages, followed by Alexa Fluor  488  -labelled 
streptavidin. Other antibodies tested were: biotin-labelled anti-
CD11b and biotin-labelled anti-F4/80 antibodies. 
  Immunoﬂ   uorescence and immunoelectron microscopy 
experiments were performed on peripheral blood lymphocytes 
(PBLs) and splenocytes collected from MRL/lpr mice that had 
received Alexa Fluor  488  -labelled P140 intravenously 1 h before 
examination. Some experiments used splenocytes incubated for 
1 h at 37°C with 5 μM Alexa Fluor  488  -labelled P140. HSC70 and 
MHCII molecules were revealed with speciﬁ  c antibodies (clone 
1B5; Stressgen (Enzo Life Sciences, Villeurbanne, France) and 
2G9; BD Biosciences (Le Pont de Claix, France)  , respectively). 
Fluorescence activated cell sorting analysis was as described 
previously.    5    The antibodies were anti-HSC70 antibody labelled 
with R-phycoerythrin (clone 1B5) and anti-IA/IE antibody 
labelled with FITC (clone 2G9). For speciﬁ  c analysis of cellular 
subtypes, antibodies used were: anti-CD3e-FITC, anti-CD3e-
allophycocyanin, anti-B220-PerCP, anti-B220-allophycocyanin, 
anti-CD4-allophycocyanin, anti-CD8-allophycocyanin, anti-
CD11b-PerCP and anti-Gr-1-FITC. HSC70 and MHCII lev-
els were expressed as the ratio of relative mean ﬂ  uorescence 
intensity for speciﬁ  c antibody/mean ﬂ  uorescence intensity for 
isotype-matched control antibody. 
  For measuring lymphocyte proliferation, MRL/lpr and CBA/J 
mice (four to ﬁ  ve/group) were given P140 peptide or ScP140 
(100 μg/mouse) or saline only, daily for 10 consecutive days 
via the intraperitoneal route. Ciclosporin A (20 mg/kg/day) and 
prednisolone (feeding at 4 mg/kg/day) were tested in parallel. 
A lymphocyte proliferation assay was performed as described 
previously    6    using 3×10  5   cells/well.   
  Statistics 
  Statistical analyses were performed using parametric (Student t 
test) and non-parametric (Mann–Whitney U) test. For all tests, 
p<0.05 was considered statistically signiﬁ  cant.     
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mice appeared to be correlated with an increased HSC70 mRNA 
expression in MRL/lpr splenocytes (  ﬁ  gure 2E  ; not visualised in 
LN cells and thymocytes). Interestingly, in MRL/lpr mice that 
received intravenous injections of 100 μg P140 daily over 6 days, 
HSC70 expression in splenic B cells was decreased by 32% 
(    ﬁ  gure 2F  ; expression of inducible Hsp70/Hsp72 protein was not 
affected). 
  Interaction of HSC70 with antigen is an important component 
of the MHCII antigen processing pathway.    10     –      14    In accordance 
  HSC70 is present at the surface of non-permeabilised MRL/
lpr and CBA/J peripheral B and T cells (notably B220+/TCRβ+ 
activated T cells and DN T cells)    5    as well as on splenic MRL/lpr 
B220–/CD3/CD11b+/MAC-1/Gr-1– monocytes/macrophages 
and B220–/CD3/CD11b+/Gr-1+ granulocytes (  ﬁ  gure  2D1  ). 
In the spleen, surface and intracellular HSC70 expression lev-
els were raised in MRL/lpr mice (  ﬁ  gure 2D   and supplementary 
  ﬁ  gure S4; observed also in LN cells, notably at the surface). The 
HSC70 expression increase observed in the spleen of MRL/lpr 
  Figure  1         In vivo effect and biodistribution of P140 peptide in MRL/lpr mice. (A, B) MRL/lpr mice received saline alone or 100 μg P140 peptide/
injection/mouse on four occasions. Kidneys were collected from 25-week-old MRL/lpr mice and ﬁ  xed in formalin. Haematoxylin and eosin-stained 
kidney parafﬁ  n sections were scored for (A) vasculitis (n=5/group; p=0.0046 between the two groups) and (B) glomerulonephritis grade (ﬁ  ve mice/
group, corresponding to 132–177 glomeruli). (C) Observation of skin lesions in both groups of 16-week-old mice. (D) In vivo biodistribution of Alexa 
Fluor  633  -labelled P140 peptide following retro-orbital injection of 100 μg peptide in NaCl (complete data in online supplementary ﬁ  gure S1). The yellow 
circle designates the position of the spleen. At the end of the experiment (180 min), organs were collected and ﬂ  uorescence was measured in the 
isolated organs (1, thymus; 2, spleen; 3, lung; 4, salivary gland; 5, axillary lymph node). (E) Spleen sections were co-stained with antibodies to B220 
and MOMA-1/CD169 to identify B cells and marginal zone metallophilic macrophages, respectively. (F) Peripheral blood lymphocyte (PBL) counts 
measured in 10-week-old MRL/lpr and CBA/J mice (n=3–4 mice tested individually/group) that received at daily intervals 10 intraperitoneal injections 
of P140 (100 μg/mouse), ScP140 (100 μg/mouse), ciclosporin A (20 mg/kg) or saline or that received prednisolone orally at a 4 mg/kg dose. (G) Effect 
of P140 overdosage on the ability of PBLs to respond to T- and B-cell mitogens. Cultures for 48 h in the presence of 3 μg/ml concanavalin A (ConA) 
or 5 μg/ml; lipopolysaccharide (LPS). NT, not tested. (H) P140 peptide administration reduces the percentage of total CD3 T cells among splenocytes. 
Splenocytes from 6-week-old MRL/lpr mice were collected 3 days after a single intraperitoneal injection of 200 μg P140 or saline (n=6/group). 
Representative results of two independent experiments are shown. *p<0.05, **p<0.01, ***p<0.001. NS, not signiﬁ  cant (Mann–Whitney U test in 
panels A, B, F and H; Student t test in panel G). Bars, 100 μm.    
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lymphoblast-like cells (  ﬁ  gure 3C  ; MHCII monomer expression 
remained unaffected). Thus, P140 associates with both HSC70 
and MHCII molecules and decreases directly or indirectly their 
surface expression on splenic B cells.   
    P140 alters autophagic processes in MRL/lpr B cells 
  It has been shown earlier in B-cell lines that manipulating APC 
expression of HSC70 modiﬁ   es the presentation of epitopes 
derived from intracellular proteins but not from exogenous anti-
gens to CD4 T cells.    14    Since HSC70 is involved in autophagy 
pathways, notably in chaperone-mediated autophagy,    14        16     –      18    
leading to endogenous MHCII loading, we explored this mecha-
nism, hypothesising that P140 might disrupt normal functions 
of HSC70 in this catabolic pathway. First, using a refolding test 
of heat-denatured luciferase by rabbit reticulocyte lysate,    7        8    we 
with observations showing that in B cells HSC70 associates 
with HLA-DRB1*0401,    10    and that HSC70 and MHCII molecules 
are associated in B-cell exosomes, for example,    15    we found 
that HSC70 and MHCII molecules staining co-localises in per-
meabilised MRL/lpr splenocytes (  ﬁ  gure 3A   and supplementary 
  ﬁ  gure S5). After in vitro incubation, co-localisation of P140 and 
MHCII molecules staining was observed in 25% of cells, and 
co-localisation of P140, HSC70 and MHCII molecules staining 
was visualised in 5–10% of cells. Interestingly, we found that 
after daily intraperitoneal injections of P140 into 12-week-old 
MRL/lpr mice, overexpression of MHCII molecules in spleen 
B cells signiﬁ  cantly decreased (  ﬁ  gure 3B  ). We thus examined 
further the effect of P140 on the stability of functional MHC 
molecules using Raji cells.    13    In a dose-dependent manner, P140 
hampered the formation of stable HLA-DRαβ dimers in these 
  Figure  2         P140 peptide interacts with HSC70 and, in vivo, diminishes HSC70 overexpression in MRL/lpr lymphocytes. (A) Pull-down experiments 
showing the interaction of P140 peptide with HSC70 at 25°C and 4°C (representative results of ﬁ  ve independent experiments). (B1) Co-localisation in 
permeabilised MRL/lpr dissociated splenocytes of P140 peptide and HSC70 examined 1 h after retro-orbital injection of 100 μg Alexa Fluor  488 -labelled 
P140 in NaCl. (B2) Co-localisation of P140 and HSC70 on spleen sections from MRL/lpr mice that received intravenously 200 μg rhodamine-labelled 
P140. (C) Co-localisation of P140 and HSC70 staining shown by immunoelectron microscopy (example with a single cell). HSC70, 15 nm gold 
particles; P140, 6 nm gold particles. (D) Fluorescence activated cell sorting analysis showing HSC70 expression at the surface of (D1) or intracellularly 
(D2) in different spleen cell subsets from CBA/J and 12-week-old MRL/lpr mice (n=5): B cells (B220+CD3), activated T cells included double negative 
T cells (B220+CD3), naïve T cells (B220–CD3), granulocytes/macrophages (CD11b+Gr-1+). HSC70 levels were expressed as the mean ﬂ  uorescence 
intensity (MFI) for speciﬁ  c antibody/MFI for isotype-matched control antibody (Ab) ratio. Error bars represent SD. Representative results of at least 
two independent experiments. (E) Levels of HSC70 mRNA detected by qRT-PCR in lymph node, splenic and thymic cells from 6- and 12-week-old 
MRL/lpr mice compared with CBA/J mice. Mean of two experiments in triplicate, normalised to actin-β expression. (F) Intracellular staining of HSC70 
and Hsp70 in splenic B cells collected from untreated or P140-treated (six times at daily intervals; 100 μg/injection/mouse) 6-week-old female MRL/
lpr mice. *p<0.05, **p<0.01, ***p<0.001 (Student t test). Bars = 100 μm, except in (C) where bars = 500 and 100 nm in the picture and inset, 
respectively.    
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  This result was conﬁ  rmed by measuring the levels of p62 
(SQSTM1/sequestosome-1), one of the speciﬁ  c substrates that 
are degraded through the autophagy-lysosomal pathway. p62 is 
selectively incorporated into autophagosomes via direct interac-
tion with LC3.    22        23    In a peptide dose-dependent manner, p62 
accumulated in P140-treated MRL/lpr B cells (  ﬁ  gure  5B  ; the 
same effect, although at a lower extent, observable in CBA/J B 
cells), again consistent with an effect of P140 on the steady-state 
autophagy in these cells.     
  DISCUSSION 
  We present evidence here that P140 seems to interfere with 
a signalling pathway engaged in lysosomal degradation, lead-
ing to instability of MHCII molecules supposed to present 
endogenous antigens to autoreactive T cells in murine lupus. 
After intravenous injection into MRL/lpr mice, P140 concen-
trates mainly in the lungs and the spleen, and in the latter it 
co-localises essentially with B cells and resident macrophages 
of the lymphoid white pulp. Its localisation (if any) is poor in 
LNs and thymus. This suggests that P140 might possess a cer-
tain degree of speciﬁ  city for targeting some but not all tissues/
organs containing HSC70+ cells, and within these tissues and 
organs, again, it seems to target certain, but not all, HSC70+ 
cell subsets. 
  We found that HSC70, which is present at the surface of 
splenic and LN MRL/lpr and CBA/J B cells, T cells (activated, 
examined in vitro whether P140 could hamper folding proper-
ties of the HSC70 molecule. At 40 and 80 μM, P140 inhibited 
luciferase refolding by 50.2% and 100%, respectively (  ﬁ  gure 4A  ; 
ScP140 showed no effect). This effect was reversed by adding an 
excess of exogenous HSC70 (  ﬁ  gure 4B  ). 
  Next, we examined P140-treated cells for altered expres-
sion of lysosomal or autophagy pathways markers. We 
studied the conversion in MRL/lpr cells of the soluble form 
of microtubule-associated protein-1 light chain 3 (LC3-I), a 
mammalian homologue of yeast Atg8, into the hydrophobic, 
mostly membrane-associated form LC3-II, which is enriched 
in the autophagic vacuole fraction but is rapidly degraded by 
lysosomal proteases when the autophagic ﬂ  ux is intense.    19    We 
observed that splenic B cells puriﬁ  ed from 8-week-old MRL/
lpr mice exhibited almost undetectable levels of LC3-I and 
rather low LC3-II levels, which were dramatically enhanced 
in the presence of lysosomal protease inhibitors E64D (cal-
pain and cathepsin B inhibitor) and pepstatin A (cathepsin D 
inhibitor) (  ﬁ  gure 5A  ). This reﬂ  ects the existence of a consti-
tutive autophagic ﬂ  ux in resting MRL/lpr B cells that can be 
blocked by speciﬁ   c inhibitors before the autolysosome for-
mation, at the fused autophagosome–lysosome step.    19    In the 
presence of P140, the basal accumulation of LC3-II expres-
sion was increased in a P140 concentration-dependent man-
ner, and strikingly, the autophagic ﬂ  ux was proportionally less 
intense (  ﬁ  gure 5A  ). This suggests that in MRL/lpr B cells, P140 
downregulates autophagic ﬂ   ux at the autolysosome stage. 
Interestingly, this stage is also affected by E64D and pepstatin 
A, for example, as well as by chloroquine,    20        21    an antimalarial 
drug used in lupus treatment.   
  Figure  3         P140 peptide interacts with major histocompatibility 
class II (MHCII) molecules and diminishes their in vivo expression. 
(A) Representative ﬂ  uorescence microscopy pictures revealing the 
co-localisation, in permeabilised MRL/lpr dissociated splenocytes, 
of P140, HSC70 and MHCII staining after a 1 h incubation at 37°C 
(bar = 5 μm). See other examples in online supplementary ﬁ  gure S5. 
(B) Expression of MHCII molecules measured by ﬂ  uorescence activated 
cell sorting analysis after daily P140 intraperitoneal administrations. 
MHCII expression measured in spleen B cells from 12-week-old MRL/
lpr mice at days 0, 2, 6 and 9 after injection, and compared with the 
expression level in those cells collected from 6-week-old MRL/lpr and 
CBA/J mice (three mice/group tested individually). Error bars represent 
SD. Differences versus 12-week-old MRL/lpr mice at day 0 were 
determined using the Student t test. *p<0.05, ***p<0.001. MFI, mean 
ﬂ  uorescence intensity. (C) P140 alters the stability of MHCII dimers 
in human lymphoma B cells. Raji cells were incubated for 24 h with 
P140 and then lysed with or without β-mercaptoethanol. Cell lysates 
were analysed by Western immunoblotting for expression of MHCII 
DRαβ dimers or MHCII DRα chain, compared with actin-β control. 
Representative results of two independent experiments.       
  Figure  4         P140 peptide alters folding properties of HSC70. (A) 
Luciferase was denatured at 40°C for 30 min and then refolded during 1 
h at 30°C with rabbit reticulocyte lysate in the presence or absence of 
increasing concentrations of P140 or ScP140. The results (expressed as 
a percentage) compare activity of renatured luciferase in the presence 
or absence of peptide. (B) The addition of increasing amounts of HSC70 
counterbalances P140 peptide inhibition of luciferase refolding in a dose-
dependent manner. Mean (SD) of two independent measurements.       
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and B and T cells proliferate normally in response to speciﬁ  c 
mitogens. We also found that the remaining B and T cells from 
P140-treated mice responded normally to mitogens. These data 
add to earlier studies showing that P140-treated and untreated 
MRL/lpr mice mount equivalent immune responses to a ﬂ  u 
virus challenge.    6    
  HSC70 protein displays numerous housekeeping 
  chaperoning functions. It is notably involved in nascent 
protein folding, prevention of protein aggregation under 
stress conditions, modulation of the assembly/disassembly 
of   protein complexes and stabilisation of RNA messengers. 
HSC70 protein acts with a series of co-chaperones including 
Nag-4, CHIP, hip, Bcl-2-associated athanogene BAG-1, BAG-3 
and Hsp40. Studies have suggested that depending on the 
cytokine   environment, HSC70 preferentially associates with 
certain of these co-chaperones leading to different effects. 
We found that P140 inhibits the ability of HSC70 to refold 
  denatured   protein. It might therefore disrupt certain interac-
tions of HSC70 with cofactors and chaperones. Future studies 
should provide insight into this topic and determine if this 
is relevant to some effects described in this study and lupus 
phenotype. 
  HSC70 is central in protein translocation across membranes 
and lysosomal transport of proteins.    24        25    It plays a pivotal role 
in chaperone-mediated autophagy in acting as a chaperone for 
unfolded substrate protein in association with the membrane 
receptor Lamp2a.    14        16     –      18        26    In certain conditions, such as an 
elevation of co-chaperone BAG-3 level, HSC70 can also associ-
ate with p62.    27    Proper turnover of p62 by autophagy is critical, 
notably to prevent spontaneous aggregate formation.    23        28     –      31    
This protein is regarded as a key signalling player in the cell 
survival/death balance. Thus, certainly the most remarkable 
information raised in this work, is the striking effect of P140 
on lysosomal degradation and class II antigen presentation 
(  ﬁ  gure 5C  ). P140 directly impairs the molecular chaperoning 
properties of HSC70 by altering its ability to promote proper 
folding of polypeptide. In MRL/lpr B cells, P140 increases 
the accumulation of the autophagy markers p62/SQSTM1 
and LC3-II, consistent with a downregulation of lysosomal 
degradation at the autolysosome stage or with a lysosomal 
dysfunction. Moreover, the expression of stable MHCII mol-
ecules is dramatically affected. This might explain our earlier 
observations showing a decreased T-cell response to various 
T-cell autoepitopes in P140-treated MRL/lpr mice    6        32    and the 
absence of lupus patient’s PBL proliferation ex vivo in the 
presence of P140.    4    
  Autophagy processes have not been explored in lupus. 
Although much has still to be determined to fully understand 
the impact of this complex pathway in MHCII presentation, 
inﬂ  ammation and central or peripheral tolerance processes, our 
studies show that a peptide that can modulate lysosomal deg-
radation can be beneﬁ  cial in MRL/lpr mice by reducing autore-
active T-cell and B-cell activation. Of importance, P140 peptide 
exerts its effects without affecting normal B and T cells, possibly 
thanks to the expression levels of HSC70, which seems to act as 
a sensor receptor on MRL/lpr B cells.             
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non-activated and DN T cells) and granulocytes/monocytes is 
progressively overexpressed in MRL/lpr spleen and LN cells. 
Intravenous administration of P140 into lupus-prone MRL/lpr 
mice leads to a decreased expression of HSC70. MHCII mol-
ecule levels are also diminished. These data reveal that after 
downstream P140 binding to HSC70, a series of molecular 
events take place affecting the APC functions of MRL/lpr B 
cells, leading ﬁ  nally to a decreased expression or stability of 
MHCII molecules and a potential reduction of autoreactive 
T-cell signalling and priming. 
  Importantly, normal lymphocytes seem to be saved from 
this process, possibly because the density of HSC70 molecules 
is insufﬁ  cient at the surface of normal APCs. The number of 
peripheral cells is not affected in P140-treated CBA/J mice, 
  Figure  5         P140 peptide alters the autophagic pathway by slowing 
down the lysosomal activity in MRL/lpr B cells. (A) Western 
immunoblotting analysis with anti-LC3-II antibodies reveals increased 
appearance of lipidated LC3-II in B cells after 24 h of in vitro P140 
treatment. Representative results of two independent experiments. 
(B) Accumulation of autophagy-selective substrate p62 visualised by 
Western immunoblotting in MRL/lpr or CBA/J B cells treated in vitro 
with P140. Representative results of two independent experiments. 
(C) A model by which P140 peptide interacts with HSC70, alters its 
properties and inﬂ  uences activation of autoreactive lymphocytes in 
lupus. (1) HSC70 is overexpressed both at the surface and intracellularly 
on lupus antigen-presenting cells (APC; B cells). (2) P140 hampers/
inhibits chaperone properties of HSC70 protein. P140 (3a) disturbs a 
complex of co-chaperones involved in the regulation of macroautophagy 
(putative) and slows down the autophagic ﬂ  ux, and/or (3b) affects 
chaperone-mediated autophagy (CMA) leading to the alteration of (auto)
antigens processing by lysosomal hydrolysis. (4) Subsequent delivery 
of antigens into MIIC compartments for class II presentation is altered 
and class II MHC molecules are destabilised, therefore compromising 
autoreactive CD4 T-cell response in a beneﬁ  cial pathway for the P40-
treated  individual.    
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